Enveric Biosciences, Inc. (ENVB)
After hours:
| Previous close | 0.5200 |
| Open | 0.5148 |
| Bid | 0.4762 x 100 |
| Ask | 0.5311 x 100 |
| Day's range | 0.4900 - 0.5299 |
| 52-week range | 0.4900 - 3.8980 |
| Volume | |
| Avg. volume | 477,712 |
| Market cap | 3.954M |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.3900 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 23 Apr 2008 |
| 1y target est | 8.32 |
Simply Wall St.Is Enveric Biosciences, Inc. (NASDAQ:ENVB) Trading At A 36% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Enveric Biosciences fair value estimate is US$0.98 Enveric...
- GlobeNewswire
Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s management commentary, recent developments, outlook, and risks. The full research report is available here. Highlights from the report include: EB-003 Elevated to Lead Development Candidate by Enveric Biosciences
Business WireEnveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
CAMBRIDGE, Mass., June 25, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the Company is prioritizing the development of EB-003, its first-in-class approach to address difficult-to-treat mental health disorders. EB-003 and other neuroplastogens developed by Enveric are designed to prom
